%0 Journal Article %T Adjuvant treatment in biliary tract cancer %A Palloni, Andrea %A Frega, Giorgio %A De Lorenzo, Stefania %A Rizzo, Alessandro %A Abbati, Francesca %A Deserti, Marzia %A Tavolari, Simona %A Brandi, Giovanni %J Translational Cancer Research %D 2018 %B 2018 %9 %! Adjuvant treatment in biliary tract cancer %K %X Biliary tract cancers (BTCs) are a heterogeneous group of malignancies with a dismal prognosis. Despite radical surgery, the five-year overall survival (OS) does not exceed 40% in the best series. Adjuvant treatments are widely used even though they have mainly been investigated in small retrospective series until recently. Available data suggest that chemotherapy with 5-fluorouracil (and relative prodrugs) or gemcitabine can reduce the risk of relapse and potentially improve patients’ long-term outcome. The role of adjuvant radiotherapy seems to be confined to patients with positive surgical margins. In addition, patients with high-risk factors for relapse (nodal involvement and non-radical resection) benefit most from chemotherapy. Recent results from large randomized trials have clarified the benefit of adjuvant treatments and probably defined a new standard of care. %U https://tcr.amegroups.org/article/view/23744 %P S289-S296 %@ 2219-6803